Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Clinical impact of the subclonal architecture and mutational complexity in chronic lymphocytic leukemia.

Nadeu F, Clot G, Delgado J, Martín-García D, Baumann T, Salaverria I, Beà S, Pinyol M, Jares P, Navarro A, Suárez-Cisneros H, Aymerich M, Rozman M, Villamor N, Colomer D, González M, Alcoceba M, Terol MJ, Navarro B, Colado E, Payer ÁR, Puente XS, López-Otín C, López-Guillermo A, Enjuanes A, Campo E.

Leukemia. 2018 Mar;32(3):645-653. doi: 10.1038/leu.2017.291. Epub 2017 Sep 19.

2.

Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia.

Nadeu F, Delgado J, Royo C, Baumann T, Stankovic T, Pinyol M, Jares P, Navarro A, Martín-García D, Beà S, Salaverria I, Oldreive C, Aymerich M, Suárez-Cisneros H, Rozman M, Villamor N, Colomer D, López-Guillermo A, González M, Alcoceba M, Terol MJ, Colado E, Puente XS, López-Otín C, Enjuanes A, Campo E.

Blood. 2016 Apr 28;127(17):2122-30. doi: 10.1182/blood-2015-07-659144. Epub 2016 Feb 2.

3.

A Quantitative Analysis of Subclonal and Clonal Gene Mutations before and after Therapy in Chronic Lymphocytic Leukemia.

Amin NA, Seymour E, Saiya-Cork K, Parkin B, Shedden K, Malek SN.

Clin Cancer Res. 2016 Sep 1;22(17):4525-35. doi: 10.1158/1078-0432.CCR-15-3103. Epub 2016 Apr 8.

4.

Targeted deep sequencing reveals clinically relevant subclonal IgHV rearrangements in chronic lymphocytic leukemia.

Stamatopoulos B, Timbs A, Bruce D, Smith T, Clifford R, Robbe P, Burns A, Vavoulis DV, Lopez L, Antoniou P, Mason J, Dreau H, Schuh A.

Leukemia. 2017 Apr;31(4):837-845. doi: 10.1038/leu.2016.307. Epub 2016 Oct 31.

PMID:
27795555
5.

IGHV gene mutational status and 17p deletion are independent molecular predictors in a comprehensive clinical-biological prognostic model for overall survival prediction in chronic lymphocytic leukemia.

Bulian P, Rossi D, Forconi F, Del Poeta G, Bertoni F, Zucca E, Montillo M, Pozzato G, D'Arena G, Efremov DG, Marasca R, Lauria F, Gaidano G, Gattei V, Laurenti L.

J Transl Med. 2012 Jan 30;10:18. doi: 10.1186/1479-5876-10-18.

6.

Frequencies of SF3B1, NOTCH1, MYD88, BIRC3 and IGHV mutations and TP53 disruptions in Chinese with chronic lymphocytic leukemia: disparities with Europeans.

Xia Y, Fan L, Wang L, Gale RP, Wang M, Tian T, Wu W, Yu L, Chen YY, Xu W, Li JY.

Oncotarget. 2015 Mar 10;6(7):5426-34.

7.

Clonal evolution in chronic lymphocytic leukemia: impact of subclonality on disease progression.

Sutton LA, Rosenquist R.

Expert Rev Hematol. 2015 Feb;8(1):71-8. doi: 10.1586/17474086.2015.972930. Epub 2014 Oct 27. Review.

PMID:
25345442
8.

COBLL1, LPL and ZAP70 expression defines prognostic subgroups of chronic lymphocytic leukemia patients with high accuracy and correlates with IGHV mutational status.

Plesingerova H, Librova Z, Plevova K, Libra A, Tichy B, Skuhrova Francova H, Vrbacky F, Smolej L, Mayer J, Bryja V, Doubek M, Pospisilova S.

Leuk Lymphoma. 2017 Jan;58(1):70-79. Epub 2016 May 17.

PMID:
27185377
9.

Genomic characterization of high-count MBL cases indicates that early detection of driver mutations and subclonal expansion are predictors of adverse clinical outcome.

Barrio S, Shanafelt TD, Ojha J, Chaffee KG, Secreto C, Kortüm KM, Pathangey S, Van-Dyke DL, Slager SL, Fonseca R, Kay NE, Braggio E.

Leukemia. 2017 Jan;31(1):170-176. doi: 10.1038/leu.2016.172. Epub 2016 Jun 14.

10.

Do biologic parameters affect the time to first treatment of clinical monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia Rai stage 0? Results of a prospective analysis.

Molica S, Giannarelli D, Levato L, Gentile M, Mirabelli R, Morabito F.

Clin Lymphoma Myeloma Leuk. 2015 Mar;15(3):e55-60. doi: 10.1016/j.clml.2014.09.003. Epub 2014 Sep 28.

PMID:
25445470
11.

Survival of Del17p CLL Depends on Genomic Complexity and Somatic Mutation.

Yu L, Kim HT, Kasar S, Benien P, Du W, Hoang K, Aw A, Tesar B, Improgo R, Fernandes S, Radhakrishnan S, Klitgaard J, Lee C, Getz G, Setlur SR, Brown JR.

Clin Cancer Res. 2017 Feb 1;23(3):735-745. doi: 10.1158/1078-0432.CCR-16-0594. Epub 2016 Aug 8.

12.

Clonal evolution, genomic drivers, and effects of therapy in chronic lymphocytic leukemia.

Ouillette P, Saiya-Cork K, Seymour E, Li C, Shedden K, Malek SN.

Clin Cancer Res. 2013 Jun 1;19(11):2893-904. doi: 10.1158/1078-0432.CCR-13-0138. Epub 2013 Apr 25.

13.

High-throughput sequencing for the identification of NOTCH1 mutations in early stage chronic lymphocytic leukaemia: biological and clinical implications.

Lionetti M, Fabris S, Cutrona G, Agnelli L, Ciardullo C, Matis S, Ciceri G, Colombo M, Maura F, Mosca L, Gentile M, Recchia AG, Ilariucci F, Musolino C, Molica S, Di Raimondo F, Cortelezzi A, Rossi D, Gaidano G, Morabito F, Ferrarini M, Neri A.

Br J Haematol. 2014 Jun;165(5):629-39. doi: 10.1111/bjh.12800. Epub 2014 Mar 2.

PMID:
24579978
14.

Detailed analysis of therapy-driven clonal evolution of TP53 mutations in chronic lymphocytic leukemia.

Malcikova J, Stano-Kozubik K, Tichy B, Kantorova B, Pavlova S, Tom N, Radova L, Smardova J, Pardy F, Doubek M, Brychtova Y, Mraz M, Plevova K, Diviskova E, Oltova A, Mayer J, Pospisilova S, Trbusek M.

Leukemia. 2015 Apr;29(4):877-85. doi: 10.1038/leu.2014.297. Epub 2014 Oct 28.

15.

Association between immunoglobulin heavy-chain variable region mutational status and isolated favorable baseline genomic aberrations in chronic lymphocytic leukemia.

Sandoval-Sus JD, Chavez JC, Dalia S, Naqvi SMH, Talati C, Nodzon L, Kharfan-Dabaja MA, Pinilla-Ibarz J.

Leuk Lymphoma. 2018 Jan;59(1):59-68. doi: 10.1080/10428194.2017.1323271. Epub 2017 Jun 22.

PMID:
28641468
16.

Array-based genomic screening at diagnosis and during follow-up in chronic lymphocytic leukemia.

Gunnarsson R, Mansouri L, Isaksson A, Göransson H, Cahill N, Jansson M, Rasmussen M, Lundin J, Norin S, Buhl AM, Smedby KE, Hjalgrim H, Karlsson K, Jurlander J, Geisler C, Juliusson G, Rosenquist R.

Haematologica. 2011 Aug;96(8):1161-9. doi: 10.3324/haematol.2010.039768. Epub 2011 May 5.

17.

Evolution and impact of subclonal mutations in chronic lymphocytic leukemia.

Landau DA, Carter SL, Stojanov P, McKenna A, Stevenson K, Lawrence MS, Sougnez C, Stewart C, Sivachenko A, Wang L, Wan Y, Zhang W, Shukla SA, Vartanov A, Fernandes SM, Saksena G, Cibulskis K, Tesar B, Gabriel S, Hacohen N, Meyerson M, Lander ES, Neuberg D, Brown JR, Getz G, Wu CJ.

Cell. 2013 Feb 14;152(4):714-26. doi: 10.1016/j.cell.2013.01.019.

18.

Chronic lymphocytic leukemia: A prognostic model comprising only two biomarkers (IGHV mutational status and FISH cytogenetics) separates patients with different outcome and simplifies the CLL-IPI.

Delgado J, Doubek M, Baumann T, Kotaskova J, Molica S, Mozas P, Rivas-Delgado A, Morabito F, Pospisilova S, Montserrat E.

Am J Hematol. 2017 Apr;92(4):375-380. doi: 10.1002/ajh.24660. Epub 2017 Feb 13.

19.

Extensive next-generation sequencing analysis in chronic lymphocytic leukemia at diagnosis: clinical and biological correlations.

Rigolin GM, Saccenti E, Bassi C, Lupini L, Quaglia FM, Cavallari M, Martinelli S, Formigaro L, Lista E, Bardi MA, Volta E, Tammiso E, Melandri A, Urso A, Cavazzini F, Negrini M, Cuneo A.

J Hematol Oncol. 2016 Sep 15;9(1):88. doi: 10.1186/s13045-016-0320-z. Erratum in: J Hematol Oncol. 2016 Sep 30;9(1):103.

20.

Clinical monoclonal B lymphocytosis versus Rai 0 chronic lymphocytic leukemia: A comparison of cellular, cytogenetic, molecular, and clinical features.

Morabito F, Mosca L, Cutrona G, Agnelli L, Tuana G, Ferracin M, Zagatti B, Lionetti M, Fabris S, Maura F, Matis S, Gentile M, Vigna E, Colombo M, Massucco C, Recchia AG, Bossio S, De Stefano L, Ilariucci F, Musolino C, Molica S, Di Raimondo F, Cortelezzi A, Tassone P, Negrini M, Monti S, Rossi D, Gaidano G, Ferrarini M, Neri A.

Clin Cancer Res. 2013 Nov 1;19(21):5890-900. doi: 10.1158/1078-0432.CCR-13-0622. Epub 2013 Sep 13.

Supplemental Content

Support Center